title: The TIR-domain-containing adapter inducing interferon-β-dependent signaling cascade plays a crucial role in ischemia-reperfusion-induced retinal injury, whereas the contribution of the myeloid differentiation primary response 88-dependent signaling cascade is not as pivotal.
abstract: Toll-like receptor 4 (Tlr4) plays an important role in ischemia-reperfusion (IR)-induced retinal inflammation and damage. However, the role of two Tlr4-dependent signaling cascades, myeloid differentiation primary response 88 (Myd88) and TIR-domain-containing adapter inducing interferon-β (Trif), in retinal IR injury is poorly understood. In this study, we investigated the contribution of the Myd88-dependent and Trif-dependent signaling cascades in retinal damage and inflammation triggered by IR, by using Myd88 knockout (Myd88KO) and Trif knockout (TrifKO) mice. Retinal IR injury was induced by unilateral elevation of intraocular pressure for 45 min by direct corneal cannulation. To study IR-induced retinal ganglion cell (RGC) death in vitro, we used an oxygen and glucose deprivation (OGD) model. Our data suggested that Myd88 was present in many retinal layers of sham-operated and ischemic mice, whereas Trif was mainly present in the ganglion cell layer (GCL). The level of Myd88 was increased in the retina after IR. We found that retinas of TrifKO mice had a significantly reduced neurotoxic pro-inflammatory response and significantly increased survival of the GCL neurons after IR. Although Myd88KO mice had relatively low levels of inflammation in ischemic retinas, their levels of IR-induced retinal damage were notably higher than those of TrifKO mice. We also found that Trif-deficient RGCs were more resistant to death induced by OGD than were RGCs isolated from Myd88KO mice. These data suggested that, as compared with the Myd88-dependent signaling cascade, Trif signaling contributes significantly to retinal damage after IR.
authors.affiliation: Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, 1638 NW 10th Ave, Miami, FL, 33136, USA.
authors.forename: Galina
authors.initials: G
authors.lastname: Dvoriantchikova
authors.forename: Andrea Rachelle C
authors.initials: AR
authors.lastname: Santos
authors.forename: Dagmara
authors.initials: D
authors.lastname: Danek
authors.forename: Xenia
authors.initials: X
authors.lastname: Dvoriantchikova
authors.forename: Dmitry
authors.initials: D
authors.lastname: Ivanov
mesh_terms: D033942:Adaptor Proteins, Vesicular Transport / Q000235:genetics / Q000378:metabolism*; D000818:Animals; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D053594:Myeloid Differentiation Factor 88 / Q000235:genetics / Q000378:metabolism*; D015427:Reperfusion Injury / Q000378:metabolism; D012160:Retina / Q000378:metabolism; D012164:Retinal Diseases / Q000378:metabolism*; D012165:Retinal Ganglion Cells / Q000378:metabolism; D012173:Retinitis / Q000378:metabolism*; D015398:Signal Transduction; D051197:Toll-Like Receptor 4 / Q000378:metabolism*
chemical_list: D033942:Adaptor Proteins, Vesicular Transport; D053594:Myeloid Differentiation Factor 88; D051197:Toll-Like Receptor 4; C507780:Myd88 protein, mouse; C476286:Ticam1 protein, mouse; C493487:Tlr4 protein, mouse
keywords: inflammation; ischemia-reperfusion injury; mouse models; retinal damage; toll-like receptor signaling
references.citation: Mol Vis. 2010 Sep 30;16:1907-12
references.pmid: 21031135
references.citation: Eur J Neurosci. 2009 Jul;30(2):175-85
references.pmid: 19614983
references.citation: Cell Death Differ. 2009 Feb;16(2):349-58
references.pmid: 18989338
references.citation: J Neurosci. 2013 Jul 17;33(29):12041-51
references.pmid: 23864690
references.citation: Prog Retin Eye Res. 2004 Jan;23(1):91-147
references.pmid: 14766318
references.citation: J Am Heart Assoc. 2014 Jan 03;3(1):e000683
references.pmid: 24390148
references.citation: Invest Ophthalmol Vis Sci. 2011 Sep 09;52(10):7187-94
references.pmid: 21828158
references.citation: PLoS One. 2008;3(10):e3596
references.pmid: 18974879
references.citation: Nat Rev Immunol. 2010 Dec;10(12):826-37
references.pmid: 21088683
references.citation: Proc Natl Acad Sci U S A. 2011 Dec 13;108(50):20054-9
references.pmid: 22123964
references.citation: FASEB J. 2011 Feb;25(2):624-31
references.pmid: 20974670
references.citation: J Neurochem. 2012 Feb;120(4):586-97
references.pmid: 22118627
references.citation: Mol Vis. 2010 Dec 28;16:2882-90
references.pmid: 21203410
references.citation: Nat Med. 2011 Nov 07;17(11):1391-401
references.pmid: 22064429
references.citation: PLoS One. 2013 Oct 11;8(10):e77123
references.pmid: 24146959
references.citation: Annu Rev Immunol. 2002;20:197-216
references.pmid: 11861602
references.citation: Med Sci Monit. 2011 Apr;17(4):RA100-9
references.pmid: 21455117
references.citation: Mediators Inflamm. 2010;2010:
references.pmid: 20706656
references.citation: J Clin Invest. 2007 Oct;117(10):2847-59
references.pmid: 17853945
references.citation: Exp Eye Res. 2001 Nov;73(5):661-7
references.pmid: 11747366
references.citation: Biochem Biophys Res Commun. 2009 Dec 18;390(3):678-83
references.pmid: 19825364
references.citation: Shock. 2009 Jul;32(1):4-16
references.pmid: 19008778
references.citation: Invest Ophthalmol Vis Sci. 2013 Aug 27;54(8):5807-16
references.pmid: 23908181
references.citation: Int Immunol. 2005 Jan;17(1):1-14
references.pmid: 15585605
references.citation: PLoS One. 2014 Jan 31;9(1):e87574
references.pmid: 24498140
references.citation: Stroke. 1996 Mar;27(3):527-35
references.pmid: 8610324
references.citation: J Biol Chem. 2011 Sep 9;286(36):31308-19
references.pmid: 21775438
references.citation: Invest Ophthalmol Vis Sci. 2008 Aug;49(8):3605-10
references.pmid: 18660426
references.citation: Med Microbiol Immunol. 2010 Feb;199(1):35-42
references.pmid: 19941004
references.citation: J Neuroinflammation. 2012 Feb 24;9:39
references.pmid: 22361049
references.citation: Invest Ophthalmol Vis Sci. 2012 May 14;53(6):2823-30
references.pmid: 22467573